Since several immunomodulatory agents, especially anti-PD1 and anti-PDL1 antibodies, have shown great promise in treating advanced NPC, the role of the PBK/CD276 axis in immunotherapy response is further to be elucidated. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.